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HEAT SHOCK PROTEINS AS NOVEL CANCER THERAPEUTICS:
TARGETING THE HALLMARKS OF CANCER
Chao Li, M.S., M.D.
ABSTRACT
Molecular chaperones, commonly known as heat shock proteins (HSPs), are essential
for mammalian cells to maintain homeostasis, and HSPs function by inducing an
ATPase-coupled structural change, followed by interactions with diverse co-chaperones and
over 200 client proteins implicated in many critical signaling networks. These highly
expressed HSPs participate in the onset and progression of several human diseases including
cancer, and their connection with tumorigenesis has facilitated research and clinical trials
related to targeting HSPs as a novel anti-tumor therapy. The predominant mechanism of
chaperone inhibition is through either disruption of the HSP association with client protein or
an altered binding state that ultimately leads to proteasome-mediated degradation.
Importantly, chaperone inhibition results in the degradation of several client proteins that
play critical roles in many of the pathways known as the Hallmarks of Cancer, such as
proliferation, angiogenesis, invasion, metastasis, and drug resistance. Here, we discuss: (1)
the current knowledge of HSPs, particularly studies related to Hsp90-targeted cancer therapy,
(2) the targeting of Hsp90-mediated signaling interactions to prevent emergence of core
Hallmarks of Cancer, (3) the recent progression of Hsp90 inhibitors in clinical trials. Finally,
we propose combinatorial therapy, additional inhibitor discovery, and location-specific
inhibition of HSPs as necessary next steps in chaperone-targeted research relevant to cancer
therapy.

CHAPTER ONE
INTRODUCTION

The eukaryotic heat shock proteins (HSPs) are a set of the most highly conserved
proteins in nature, collectively known as essential and ubiquitous molecular chaperones for
their cytoprotective functions during the maintenance of organism homeostasis under both
physiological and pathological conditions (Lindquist 1988; Hendrick et al 1993).
Mammalian HSPs have also been recognized to play a series of critical roles in tumorigenesis,
as well as their function in protein assembly and the prevention of protein misfolding and
aggregation under stress conditions. Chaperones are divided into four major families, Hsp90,
Hsp70, Hsp60, and Hsp20, according to their relative molecular mass (Calderwood et al
2006; Jego et al 2010), while additional novel families include Hsp110 and Hsp170 (Easton
et al 2000). In order to survive under the harsh conditions within the tumor
microenvironment, cancer cells typically become dependent on stress-inducible HSPs in
order to become refractory to chemotherapy, tolerant to hypoxia, resistant to apoptosis, and to
suppress antitumor immunity, all the while acquiring the properties of invasiveness and
metastasis during cancer progression. To date, more than 200 HSP client proteins have been
identified involving nearly all fundamental cellular activities and processes, including cell
growth, proliferation, and cell survival (Jego et al 2010). Interestingly, many
cancer-associated proteins have been reported as HSP clients, likely as a mechanism for
promoting oncogenic transformation. Therefore, targeting HSPs would result in simultaneous
inhibition of multiple signaling pathways responsible for modulation of various events
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involved in cancer progression for a broad range of tumor types, such as neoplastic growth,
sustained angiogenesis, chemotherapeutic resistance, evasion of cell death, and ultimately,
invasion and metastasis (Barginear et al 2008).
Although the exact molecular mechanism(s) of HSP inhibitors have not yet been fully
determined, a significant number of client proteins are either part of mechanistic studies
(bench) or under evaluation as part of clinical trials (bedside). For example, histone
deacetylase (HDAC) inhibitors as novel anticancer agents are found to hyperacetylate Hsp90,
causing an increase in its binding to an Hsp90 inhibitor now in phase II trials, ultimately
showing anti-tumor activity in leukemia and prostate cancer (Barginear et al 2008).
Glucose-regulated protein 78 kD (GRP78), also known as immunoglobulin heavy chain
binding protein (BiP), is a member of the HSP family of molecular chaperones and serves as
an unfolded protein response marker. GRP78 is involved in cellular adaptation and survival
to facilitate tumorigenesis through active interaction with a variety of partners/ligands within
tumor cells (Dudek et al 2009). On the basis of shared homology with other HSP family
proteins, GRP78 is also a molecular target of HDAC inhibitors, resulting in the
phosphorylation and activation of initiating factor 2α (p-IF2α) and an increase in ATF4 and
C/EBP homologous protein synthesis (Kahali et al 2010), all of which are important for
progression of certain cancer types.
Thus, overall, HSPs are implicated in cancer and have been shown to specifically
interfere with current antitumor therapies that target phenotypic responses like apoptosis,
necrosis, autophagy, and senescence. Not surprisingly, inhibition of Hsp90’s ATPase activity
and disruption of ongoing chaperone folding cycles results in dissociation, destabilization,
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and proteasomal degradation of a variety of client proteins, including the cancer-associated
targets ErbB1, ErbB2, Bcl-2, Apaf-1, Akt, and MMP-2 (Jego et al 2010; Wang et al 2009).
Even though clinical trials often show inherent toxicity of Hsp90 inhibitors and strong
induction of cytoprotective function of Hsp70, a combination of Hsp90 and Hsp70 inhibitors
with traditional chemo- and/or radio-therapy may provoke tumor regression in a synergistic
manner.
Here, we will review studies describing the connection between molecular chaperones
and tumorigenesis, especially focusing on the roles of the molecular chaperone families
Hsp90 and Hsp70 (for example, GRP78). We start by reviewing our current understanding of
the roles of individual chaperone family members in malignant progression and other types
of diseases. We then focus on available strategies employing specific Hsp90 inhibitors in
certain types of cancer to alter the Hallmarks of Cancer. Finally, we will evaluate potential
novel approaches such as combinatorial therapy including inhibitors for Hsp90 and discuss
future directions to improve the effects of anti-tumor treatment.
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CHAPTER TWO
CYTOPROTECTIVE FUNCTIONS OF HSPS

A. HSP Function in Protein Folding and Degradation
Molecular chaperones are essential for nascent polypeptides or proteins to fold correctly
and prevent them from degradation and aggregation in an intracellular environment.
Understanding of the molecular mechanisms of how different proteins synthesized in the cell
use specific molecular chaperone machinery will provide fundamental implications for both
translational research and the clinic practice.
Most heat-shock proteins (HSPs) and their constitutively-expressed relatives are
ubiquitously expressed under normal conditions to protect cells from the dangerous
consequences of protein misfolding and aggregation. Highly expressed HSPs are considered
key components in the cellular protective response to various cytotoxic exposures including
temperature, hypoxia, inflammation, starvation, radiation, infection, heavy metals, and acidic
conditions. The induction of HSP expression is at least partially controlled by the specific
transcription factor heat shock factor 1 (HSF1) and also by other oncogenic signaling
proteins such as heregulin-HER2-PI3K (Calderwood et al 2006; Workman et al 2007). HSF1
monomers are complexed with the Hsp90 chaperone in the cytoplasm of cells, rendering both
proteins functionally inactive. Only under stress-inducing conditions the interaction is
disrupted, likely through phosphorylation events, and the functional HSF1 trimer induces
transcriptional upregulation of HSPs (Voellmy et al 2004; de Billy et al 2009; Pirkkala et al
2001). HSP stimulation allows for an increase in the critical pathways responsible for
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protecting cells from destruction (e.g. cell death pathways). Importantly, each member of
HSP family plays a unique role in cytoprotection. Many of these key proteins will be
discussed in more details in the subsequent sections.

A1. Hsp90: Hsp90α and Hsp90β
Hsp90 is unique among the chaperones because it is not necessary for the biogenesis of
most polypeptides; rather, it seems to control aspects of protein activity, stabilization, and
complex assembly. There are over 200 Hsp90 identified “client proteins” or cellular
substrates reported to interact with Hsp90, compromising a variety of functional pathways
for cell growth, proliferation, and survival (Figure 1). Many of these clients are bona fide
oncoproteins involved in oncogenic signal transduction implicated in tumor progression (for
an updated list, refer to: http://www.picard.ch/downloads/HSP90interactors.pdf). Hsp90 is
composed of three functional domains: an amino-terminal ATP binding domain, a charged
middle linker domain with high affinity for client protein binding, and a carboxy-terminal
dimerization domain. Hsp90 undergoes modulated nucleotide-dependent cycling of ATP
binding and hydrolysis, with ultimate release of the modified client protein. Different
post-translational modifications including phosphorylation, acetylation and S-nitrosylation
may affect the function of Hsp90. The most prevalent members of the Hsp90 family are
Hsp90α and Hsp90β isoforms (also called HSPC1 and HSPC3, respectively), which are
expressed by two distinct genes whose protein products are mainly cytoplasmic. So far only
Hsp90 α has been reported to stabilize MMP-2 and prevents it from degradation in cancer
cells through the interaction between the Hsp90α middle domain and the MMP-2 C-terminal
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FIGURE 1. Current therapeutic targeting of the hallmarks of cancer using Hsp90
inhibitors. Drugs targeting Hsp90 in certain forms of cancer either through competitive
binding to N-terminal or C-terminal of Hsp90 thereby prevention of ATP-dependent Hsp90
cycle eventually leading to client proteins degradation. The genes listed are illustrative
examples implicated in the development of the hallmarks of cancer. There is a vast amount of
literature reports with different molecular therapeutic targets in vitro and in vivo alone or in
combination to modulate most of the hallmarks of cancer. So far two hallmarks of cancer
regarding to Hsp90 inhibitors for the cancer therapy are still under development, which hold
a promise for future research as potential cancer therapeutics. FNACA, Fanconi anemia
complementation group A. Akt, protein kinase B. VEGF, vascular endothelial growth factor.
SDF-1, stroma derived factor-1. IL-8, interleukin-8. IL-6, interleukin-6. ER, estrogen
receptor. PR, progesterone receptor. HER-2, human epidermal growth factor receptor-2.
RTKs, receptor tyrosine kinases. MMP-2, matrix metalloproteinases-2. MAPK,
mitogen-activated protein kinase.
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hemopexin domain (Song et al 2010).
Hsp90 inhibition has attracted considerable attention in the past two decades as a
promising approach for cancer therapy, leading to degradation of multiple oncogenic client
proteins. A number of compounds and their derivatives have been shown to bind the ATP
binding pocket of Hsp90, which prevents ATP hydrolysis and blocks protein folding and
assembly. Instead, Hsp90 inhibition results in the targeting of its client proteins to a
proteosomal degradation pathway. In addition, molecular mechanisms underlying Hsp90
translocation to the extracellular matrix and nucleus still remain obscure, even though
secretion can be observed after stimulation by stressful conditions, growth factors, and
influenced by phosphorylation and acetylation of the chaperone. Tapia and Morano recently
discovered a novel targeting event of Hsp90 into the nucleus from the cytoplasm upon
glucose exhaustion in the yeast. They employed an Hsp90-Green Fluorescent Protein (GFP)
fusion protein to show nuclear accumulation of Hsp90 was a specific response to transition
through the shift into quiescence (Tapia et al 2010). In another study, Diehl et al found
elevated nuclear Hsp90 expression during breast cancer progression, which suggested that
nuclear Hsp90 could be an indicator of malignancy and a viable target for cancer therapy
(Diehl et al 2009). Previous studies also indicated both Hsp90 and Hsp23 were involved in
specific nuclear events. In one study, Hsp90 and Hsp23 were demonstrated to promote
telomerase activity by enhancing telomerase binding to DNA as well as nucleotide
processivity (Forsythe et al 2001). In higher eukaryotes, the Hsp90/Hsp70 chaperone
complex is required for proper delivering p53 and steroid receptors such as glucocorticoid,
androgen and oestrogen receptors into nucleus thus promoting their DNA binding activities.
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In summary, these reports shed light on the roles of Hsp90 involved in translocation of client
proteins into nucleus as part of its chaperone functional cycles. How can nuclear Hsp90 and
its client proteins be targeted? Searching for specific approach to deliver Hsp90 inhibitors
into the nucleus of cancer cells becomes an interesting question to be addressed for cancer
therapeutics. For example, the use of silicon-based drug delivery vectors would be a good
choice for cancer treatment and imaging, which will facilitate the delivery of multiple
nano-components to particular cell compartments to achieve site-directed delivery of drugs.
An in vitro study showed that the internalization of porous silicon microparticles by
endothelial cells and macrophages is compatible with all the cellular physiological process
including cell morphology, intracellular transportation, cell cycle and mitosis, cytokine
secretion, and cell viability (Serda et al 2011).

A2. Hsp70 Family
Hsp70 family members are not only responsible for protein conformational assembly, but
also preventing protein misfolding and aggregation during a variety of post-translational
processes including protein targeting and degradation, membrane translocation, and apoptosis.
The HspA group of HSPs includes Hsp71, Hsp70, Hsp72, and GRP78 (BiP). The members of
this Hsp70 family represent the most highly conserved molecular chaperones. They have two
major functional domains: an N-terminal ATPase-binding domain (ABD) responsible for
substrate binding and refolding, and a C-terminal peptide-binding domain (PBD) to facilitate
the release of client protein after ATP hydrolysis.
The 78-kDa glucose regulated protein (GRP78), also well known as immunoglobulin
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heavy chain binding protein (BiP), was originally found as a major protein for maintaining
intracellular homeostasis in endoplasmic reticulum (ER) called the unfolded protein response
(UPR). High level of GRP78 confers multiple survival advantages to facilitate the
proliferation of cancer cells through harsh conditions and to acquire chemotherapeutic
resistance (Gonzalez-Gronow et al 2009; Dong et al 2008; Lee, 2007; Lee, 2001; Li et al
2006). While it is difficult to detect GRP78 expression in normal cells, over-expression of
GRP78 can be detected in many tumor cell lines and primary tumors, such as breast and
prostate cancer cells. In vivo studies demonstrate a critical role of GRP78 in tumor growth,
metastasis, and angiogenesis in xenograft models and in the Grp78 heterozegous mice with
partial reduction of GRP78 (Lee, 2007). It has been shown that GRP78 interacts with BH-3
only proapoptotic protein, Bcl-2 Interacting Killer or Natural Born Killer (BIK, or NBK) and
specific caspases, such as caspase-7, on the ER membrane, thereby regulating the balance
between cell survival and apoptosis (Rao et al 2001; Fu et al 2007; Rauschert et al 2008;
Reddy et al 2003). GRP78 is commonly found inside the ER lumen because of a presumed
N-terminal ER localization signal. GRP78 can be detected as a cell surface protein in a broad
variety of tumor cells by global profiling of the cell surface proteins, suggesting cancer cells
may have evolved a specific mechanism for presenting GRP78 epitopes on the cell surface
(Gonzalez-Gronow et al 2009; Misra et al 2006; Misra et al 2010).
Hsp72 is another major heat shock-induced protein capable of protecting cells from
stressful conditions. Hsp72 can be present at elevated levels in various forms of tumors and
in many transformed cell lines. It has been shown that the oncogenic potential of Hsp72 is
confined in its peptide binding domain since the expression of this domain alone was
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sufficient for tumorigenic transformation of Rat-1 cells (Volloch et al 1999). Based on more
novel findings of roles of Hsp70 from clinical and basic research, Hsp70 targeted therapy is
clearly an attractive approach for anti-tumor treatment. Considerable progress has been made
in targeting Hsp70 using small molecule inhibitors in cancer as well as in other protein
folding diseases. In this review, we will focus on small molecule inhibitors targeting Hsp90.

A3. Hsp60
In eukaryotes, the chaperonin proteins Hsp60 and Hsp10 are structurally and
functionally nearly identical to the bacterial GroEL and GroES proteins, respectively.
Hsp60/GroEL belongs to the molecular chaperones in the alkalai family. GroEL requires the
lid-like cochaperonin protein complex GroES to function normally to help proteins fold
correctly. Hsp60 is involved in protein folding after its post-translational import to the
mitochondria (or chloroplasts in plants). These chaperonins aid the folding process by
assembling into large complexes to provide specific folding spaces where clients can undergo
the appropriate intramolecular interactions to obtain the correct three dimensional structure.
Accumulating data showed alteration of Hsp60 expression in tumor development.

It has

been demonstrated Hsp60 as an intramitochondrial protein directly interacts with cyclophilin
D (CypD), a component of the mitochondrial permeability transition pore, thereby preventing
CypD-dependent cell death through formation of a multiple complex with Hsp90, and tumor
necrosis factor receptor-associated protein-1 in tumors (Ghosh et al 2010). However, Hsp60
has also been found in the cytosol, cell membrane, vesicles, extracellular space as well as
serum (Cappello et al 2011). The elucidation of molecular mechanism of Hsp60 distribution
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in different cellular compartment may provide a novel target for cancer therapy. For example,
Chun et al demonstrated the cytosolic Hsp60 promoted the TNF-α-mediated activation of the
IKK/NF-κB survival pathway via direct interaction with IKKα/β in the cytoplasm.
Mechanism for IKK activation by the cytosolic Hsp60 was showed to work via up-regulating
the activation-dependent serine phosphorylation in a chaperone-independent manner, which
indicated the role of Hsp60 for tumor cell survival may work through NF-κB pathway (Chun
et al 2010).

A4. Hsp27 and the small HSPs
Protein folding also involves the Hsp27 family, known as the small HSPs (sHSPs, 15-30
kDa). They assemble into large aggregates that mediate holding and folding in an
ATP-independent manner, which differs from the larger ATP-dependent molecular
chaperones (e.g. Hsp90). The common functions of sHSPs are chaperone activity,
thermotolerance, inhibition of apoptosis, regulation of cell development, and differentiation
(Garrido et al 2006). Hsp27 belongs to a family of sHSPs that includes ubiquitin,
α-crystallins, Hsp20, and others. sHSPs have significant sequence homology and biochemical
properties in common including phosphorylation and oliogmerization. Hsp27 contains a
central domain called α-crystallin, which is universally conserved among all the sHSPs
family members. The N-terminus is made of a less conserved region, called WDPF motif
representing amino acid (16-19 residues) tryptophan, aspartate, proline, and phenylalanine,
which is necessary for chaperone-like activity of sHSP, since substrate binding occurs
through hydrophobic interactions (Takeuchi 2006). The WDPF motif affects the Hsp27’s
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oligomerization, which is regulated by the phosphorylation of the protein. Hsp27 may serve
as a differentiation marker since it is induced in the early stages of differentiation, decreasing
when a cell divides.
Hsp27 enhances the activation of the nuclear factor-κB (NF-κB) pathway, which
controls many pathophysiological processes, such as tumor cell proliferation, inflammation,
drug resistance, and stress response (Romani et al 2007; Andrieu et al 2010). The
cytoprotective properties of Hsp27 result from its ability to modulate reactive oxygen species
(ROS) and to raise glutathione levels in its reduced (non-oxidized) form.

A5. Hsp40 family
Hsp90 and Hsp70 are relatively thoroughly investigated for their roles in molecular
mechanisms underlying tumor pathogenesis. However, the role of DnaJ/Hsp40 family in
physiological and pathological conditions is still to be further investigated. Because
hydrolysis of ATP is essential for Hsp70s activities, DnaJ/Hsp40 proteins stabilize Hsp70s
interaction with client proteins through binding to the ATPase domain of Hsp70 particularly
with its conserved tripeptide of Histidine-Proline-Aspartic acid (HPD) motif in the J domain
(Tsai J et al 1996; Qiu et al 2006). The J domain is usually located at the N-terminal region
of the DnaJ/Hsp40 proteins and composed of a 70-amino acid sequence forming four helices
and a loop region containing the HPD motif between helices II and III. Depending on the
presence of the Gly/Phe-rich region (G/F) with/without the cysteine repeats, DnaJ/Hsp40
proteins can be categorized into type I, II and III.
Several studies have shown that several Hsp40 family members including hTid I (class
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DNAJA3) and HLJ 1 (class DNAJB4) are associated with the regulation of tumor
progression (Kim et al 2004; Wang et al 2005). In addition, some DnaJ family members have
unique domains which display the functional diversity of these proteins. For example, the
mammalian DnaJ protein ERdj5, as a novel endoplasmic reticulum (ER) chaperone, has an
unique combination of domains including a danj, a protein disulfide isomerase-like and a
thioredoxin domain (Cunnea et al 2003; Hosoda et al 2003). Recently, Ushioda et al reported
that ERdj5 has a reductase activity; it can cleave disulfide bonds of misfolded proteins and
accelerates ER-associated degradation (ERAD) through its interactions with ER
degradation-enhancing α-mannosidase-like protein (EDEM) and BiP/GRP78 (Ushioda et al
2008 & 2011). Thomas et al reported that ERdj5 enhanced apoptosis in neuroblastoma cells
utilizing its dnaj domain to block the ER stress-induced phosphorylation of eukaryotic
translation initiation factor 2α (eIF2α) and the subsequent translational suppression (Thomas
et al 2009). The compromised UPR was observed in ERdj5-overexpressing ER-stressed cells.
This was due to inhibition of eIF2α phosphorylation which impaired neuroblastoma cell
survival under ER stress conditions. These findings indicated that ERdj5 reduced
neuroblastoma cell survival through negative regulation of the UPR, providing the possibility
that this chaperone protein could be a novel target for cancer therapy.

A 6. HOP
Hsp70/Hsp90 organizing protein (HOP) is one of the most extensively studied
co-chaperones, which is able to directly associate with both Hsp70 and Hsp90. The current
dogma proposes that HOP functions primarily as an adaptor that directs Hsp90 to
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Hsp70-client protein complexes in the cytoplasm (Odunuga et al 2004). However, mounting
studies indicate that HOP can also associate with a number of Hsp90-independent complexes
including the intriguing role as a receptor for prion proteins (Martins et al 1997; Romano et
al 2009).
The diverse location of HOP inside of the cell, the versatility of tetratricopeptide (TPR)
domain, coupled with the association with various other cellular Hsp90-independent proteins
uncovered novel roles of HOP. For example, Marozkina et al recently showed HOP is a
critical target of S-nitrosoglutathione (GSNO), and its S-nitrosylation by GSNO inhibited the
association of HOP with DeltaF508 cystic fibrosis (CF) transmembrane conductance
regulator (CFTR) in the ER. This effect was necessary and sufficient to mediate
GSNO-induced cell-surface expression of DeltaF508 CFTR. HOP siRNA recapitulated the
effect of GSNO on DeltaF508 CFTR maturation and expression. In summary this study
demonstrated that GSNO corrects DeltaF508 CFTR trafficking by inhibiting HOP expression,
and the combinational therapies targeting different mechanisms of action may have additive
treatment beneficial for CF (Marozkina et al 2010).

B. Functional Role of HSPs in Cancer Development
Molecular chaperones are essentially housekeeping proteins as they function to: 1) assist
nascent protein folding, 2) prevent misfolding, and 3) reduce aggregation of unfolded or
misfolded proteins during stressful conditions. In transformed cells, mechanisms for
controlling protein aggregation are critical for preventing cell death that can be induced by
the increase in cell stress and the ultimate loss of cellular homeostasis. Interestingly, these
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pathways are interrelated with an underlying theme: cancer initiation and progression. A list
of major key cancer-associated mechanisms is discussed in this section.

B1. Diversified roles of HSPs in cell death pathways
As transformed cells develop, their microenvironment plays an important role in tumor
cells ability to progress to a more aggressive phenotype. During this time of adaptation to
their surrounding environment, tumor cells develop survival capabilities through several
known and unknown mechanisms in order to acclimate to stressful conditions that
accompany

tumor

progression,

including

inflammation,

hypoxia,

radiation,

and

chemotherapy. HSPs can protect tumor cells not only from apoptosis induced by a variety of
diverse stimuli but also from type II programmed cell death (i.e. autophagy), replicative
senescence, and mitotic catastrophe.

B1.1 Apoptosis
HSPs regulate the intrinsic apoptotic signaling pathway (mitochondrial). Hsp90 and its
co-chaperones also modulate and mediate tumor cell apoptosis through interacting with the
Akt kinase, tumor necrosis factor (TNF) receptor, HER2/ErbB2 receptor, and transcription
factors like NF-κB. However, Hsp90 plays a more significant role during oncogenic
transformation than simple inhibition of apoptosis. Using genetic and pharmacological
techniques, Hsp90 has been shown to facilitate numerous transient low-affinity
protein-protein interactions that were previously unknown, partly because these client
proteins become actively involved in oncogenic transformation (Basso et al 2002; Vanden et

16

al 2003; Chen et al 2002; Xu et al 1999; Zhang et al 2008). For instance, wild type SRC
tyrosine kinase needs only limited assistance from the Hsp90 chaperone machinery for
assembly into its mature and functionally active protein; yet v-SRC mutants demonstrated an
uncommonly stable interaction with Hsp90 (Oppermann et al 1981; Brugge et al 1983). This
aberrant interaction between chaperone and mutated client protein was later shown to be
essential for acquiring and maintaining the transforming activity of v-SRC in tumor cells (Xu
et al 1993; Whitesell et al 1994). Because of the accumulation of such mutant proteins in
tumor cells, novel phenotypes may emerge as a result of alterations in the levels of unbound
or uncomplexed Hsp90, which can be virtually eliminated by environmental stress and/or
tumorigenic transformation. Numerous in vitro studies suggested an important role for HSPs
in the regulation of caspase activation because they were able to block cell death at different
stages by interaction with a number of apoptosis-related client proteins.
Hsp27 is actively involved in the apoptotic pathway. Hsp27 interacts with the outer
mitochondrial membrane and sequesters cytochrome C, which was released into the cytosol
from the mitochondria, thereby preventing the formation of the apoptosome and the
activation of procaspase-9. In addition, knockdown of Hsp27 by siRNA induces apoptosis
through activation of caspase-3.
Hsp70 is a negative regulator of the intrinsic apoptotic pathway and can inhibit cell death
at different stages. At a premitochondrial stage, Hsp70 suppresses stress inducing signals
through binding to c-Jun N-terminal Kinase (JNK1) via an ATPase domain independent
manner (Park et al 2001; Mosser 2000), as well as binding to nonphosphorylated protein
kinase C (PKC) and AKT (Gao et al 2002), resulting in their stabilization, at the
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mitochondrial stage, Hsp70 prevents Bax translocation to inhibit mitochondrial membrane
permeabilization (Stankiewicz et al 2005). Finally, Hsp70 functions at the post-mitochondrial
level by interacting with the apoptosis-inducing factor (AIF) and the apoptosis protease
activating factor-1 (Apaf-1) or by protecting essential nuclear proteins from caspase-3
cleavage (Li et al 2000).

B1.2 Autophagy
sHSPs are reported to act at different steps in protein quality control with differential
potential to prevent aggregation of insoluble mutant proteins. Aggregation of polyglutamine
proteins results in the development of neurological disorders such as Huntington disease and
spinocerebellar ataxias. One of the HSP family members, HSP7 can prevent toxicity of
polyglutamine-containing proteins in cells by assisting the loading of misfolded proteins or
small protein aggregates into autophagosome. However, the mechanism of heat shock 27kDa
protein family, member 7 (HSPB7) involvement with the autophagic machinery has yet to be
investigated. Recently, Jiang et al reported Hsp90-mediated inactivation of NF-κB signaling
pathway turned protective autophagy into apoptosis in human leukemia NB4 cells when
treated with sodium selenite, which was an essential dietary component for animals and
humans considered as a protective agent against cancer. In their study, reduction of Hsp90 in
selenite-treated NB4 cells attenuated IKK/NF-κB signaling pathway and led to inhibition of
autophagy-related gene (Atg) 6 expression (also known as Beclin 1) and vesicular
accumulation of microtubule-associated proteins 1 light chain 3 (LC3), both of which are the
markers of autophagic activity, thereby activating apoptotic pathway in these cancer cells.
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These findings suggested that the potential role of overexpression of Hsp90 may be served as
a protective factor for drug resistance in some types of cancer (Jiang et al 2011).

B1.3 Necrosis, Telomerase and ROS
Small HSPs, especially Hsp27 and α-crystallin, can protect cardiomyocytes from
ischemia-induced necrosis both in vitro and in vivo, while the larger Hsp70 protein protects
human β-cells from nitric oxide-induced necrosis via rescue of mitochondria functions. The
potential mechanisms of this phenomenon may be associated with inhibition of the stress
kinases JNK and p38 by Hsp70, indicating that these kinases are targets of the anti-necrotic
effect of Hsp70 in the myocardium. Although the molecular mechanisms of HSPs in
protection of cancer cells from ischemia-induced necrosis has not yet been reported, it may
be interesting to investigate the effect of Hsp70 on JNK and p38 regarding to higher levels of
expression of Hsp27 and/or Hsp70 in tumor versus normal tissue. Akalin et al showed Hsp90
chaperone-mediated enhancement of telomerase assembly contributed to tumorigenic
conversion. In the same study, telomerase activity was dramatically increased as prostate
cancer cells progressed to tumorigenic state in vitro using an appropriate prostate cancer
model system within a similar genetic background (Akalin et al 2001). The interactive
relationship among stress, telomeres, telomerase and molecular chaperones needs to be
further examined. Therefore, telomerase inhibition as a potential adjuvant therapy to
anti-tumor approaches becomes appealing if Hsp90 inhibition can affect telomerase activity
at low doses without detrimental effects. In addition, it has shown that chronic inhibition of
Hsp90 using an established antibiotic inhibitor, radicicol, resulted in telomere shortening and
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subsequent cell death through the generation of reactive oxygen species (ROS) through the
deregulation of the NOS pathway with a significant increase in NOS-dependent O2- radicals
(Compton et al 2006).

B2. Angiogenesis
High levels of HSP expression are important for cancer cells to survive in a hypoxic
tumor microenvironment, which is generally attributed to their effects on the transcription
factor HIF-1α by mediating its stabilization and/or aggregation. HIF-1 is a heterodimer that is
composed of both HIF-1α (120 kD) and HIF-1β (91-94 kD). HIF-1α is stabilized by Hsp90 in
hypoxic conditions and normally degraded by prolyl hydroxylase (PHD), the von
Hipple-Lindau

(VHL)/Elongin-C/Elongin-B

E3

ubiquitin

ligase

complex

through

proteasomes dependent manner ( Liu et al 2007; Isaacs et al 2003; ).
Hsp90 plays a critical role in structural modulation of oncoproteins including Akt,
HER-2/ERBB2, RAF1, eNOS, BCR-ABL and mutated p53 (Kim et al 2008; Bohonowych et
al 2010). Hypoxia and other stressful stimuli induce HIF expression as well as subsequent
cellular response, resulting in a cascade of signaling events that induce VEGF expression and
angiogenesis. Importantly, several critical mediators in this angiogenic signaling pathway,
including HIF, VEGF-receptor and IL-8/NF-κB are dependent upon Hsp90 for their function.
Receptor Tyrosine Kinase (RTK) activation also potentially induces HIF expression via
Akt/mTOR -mediated translation pathway. RTKs additionally transactivate Ephrin type-A
receptor 2 (EphA2), a novel Hsp90 client protein known to be involved in tumor
angiogenesis. In addition, HIF also promotes the expression of several RTK ligands, for
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example, hepatocyte growth factor (HGF) and TGF-α, as well as RTK receptors including
endothelia growth factor receptor (EGFR) and insulin-like growth factor receptor (IGFR),
thereby reinforcing these signaling interactions. Moreover, Hsp90 plays a role in
NF-κB-induced VEGF expression and regulates downstream effectors, including
Akt-mediated eNOS phosphorylation. Given that Hsp90 is required for activation of VEGFR,
Akt, eNOS, and NFκB, Hsp90 inhibitors can be employed to target multiple signaling
molecules of angiogenesis pathway, as demonstrated by the potent suppression of VEGF and
NO release both in vitro and in vivo with the overall outcome of inhibiting tumor
angiogenesis (Bohonowych et al 2010).
Lang et al showed that Hsp90 inhibitors can also disrupt HIF-1α/Signal Transducer and
Activator of Transcription-3 (STAT3) mediated autocrine loop for IL-6 and IGF-I in
pancreatic adenocarcinoma cells and the highly metastatic L3.6p1 pancreatic cells by direct
disturbance with the functions of HIF-1α and STAT3. In the same study, ELISA data also
demonstrated a marked reduction of VEGF-A expression after treatment with
17-allylamino-geldanamycin (17-AAG), a Hsp90 inhibitor (Lang et al 2007). In tumor cells,
STAT3 is commonly activated and blocks apoptosis as wells promotes cell transformation.
Much of the known roles of Hsp90 in angiogenesis is shown schematically in Figure 2.
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FIGURE 2. Hsp90 inhibitors targeting angiogenic signaling network in cancer. Hsp90
mediates multiple channels of angiogenesis signaling in cancer cells through its interaction
with multiple client proteins including HIF-alpha, RTKs, AKT, and NF-κB. Traditional
oncogenic angiogenesis pathway works through HIF-dependent manner, which can be
activated either by direct stimulant, hypoxia or through phosphorylation of several tyrosine
kinase receptors (RTKs) thereby activating downstream HIF-1 α-associated pathways
including RTKs-PI3K/Akt-HIF-alpha-VEGF and RTKs-MAPK-HIF-alpha-VEGF. In
addition, recruitment of bone marrow derived cells (BMDC) stimulates a proangiogenic
factor IL-8 secretion to activate NF-κB-dependent VEGF expression. Recently, several
studies showed NF-κB induced HIF-alpha expression in transformed cells and canonical
NF-κB pathway is required for inflammatory gene expression when exposed to hypoxia
(Qiao et al 2010; Fitzpatrick et al 2011). Over all these findings indicate that a complicated
signaling network intertwined for collaboration of angiogenesis in cancer, which provides a
strong evidence for Hsp90 inhibitors to be considered as multi-targets-inhibition strategy for
clinical trial.
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B3. Invasion and Metastasis
Over-expression of heat shock factor protein 1 (HSF1) and HSPs in tumor cells displayed
an increasing trend to invade tumor microenvironment and metastasize to distant sites
(Ciocca et al 2005; Hoang et al 2000), though molecular mechanisms have not yet fully
understood. In addition to transcriptional regulation of HSPs expression, recent data also
showed that HSF1 is an important facilitator for tumor progression. Accumulating research
suggests that highly expressed downstream factors of HSF1, including Hsp27 and Hsp70, in
tumor cells are at least partially responsible for the invasive and/or metastatic properties of
tumors.
Hsp90 was detected on the cell surface and in conditioned medium of tumor cells, where
it acted as a molecular chaperone to assist in the activation of matrix metalloproteinase-2
(MMP-2), working with a complex of co-chaperone proteins including Hsp90 organizing
protein (HOP) and p23, leading to elevated tumor invasiveness. Accumulating evidences
indicate that Hsp90 especially Hsp90α can be expressed and function in the extracellular
space acting as a molecular chaperone that assist in the maturation of pro-MMP2 to its active
form by stimulating propeptide cleavage. Activated MMP2 protease digests many of the
major extracellular matrix (ECM) components surrounding tumor tissue including
fibronectin, laminins, collagens, etc thereby facilitating tumor invasion process. As an
ubiquitously expressed cytosolic protein in higher eukaryotes, Hsp90α also works in other
cellular compartments in different cell types and specific disease conditions playing
distinctive biological functions.
Several cochaperones including p23 and HOP were found in the conditioned medium of
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HT-1080 fibrosarcoma cells acting in concert with Hsp90α to activate MMP2. In addition,
p23 was also shown to promote tumor progression and poor prognosis in breast cancer by
increasing metastatic potential through the upregulation of several genes involved in
metastasis and chemotherapeutic resistance by enhancing Akt signaling pathway, which plays
a critical in tumorigenesis. These findings opened a new door to target extracellular Hsp90
and related chaperone complex for cancer therapy. However, there are still several important
questions that need to be addressed before we become excited about these novel findings. For
example, neutralizing antibody against extracellular Hsp90 only affects the regulation of cell
migration and metastasis but did not affect tumor cells proliferation both in vitro and in vivo.
Two possible explanations can be considered. First, Akt/PI3K signaling pathways are
involved in cell survival and metastasis. Both of them are Hsp90 client proteins. Hence
blockage of Hsp90 activity seems to activate apoptosis through attenuation of Akt/PI3K
oncogenic pathways. Second, heregulin-induced HER2 phosphorylation in tumor cells can be
ameliorated by neutralizing antibody against extracellular Hsp90 which inactivates
downstream kinase signaling pathways, rearranges cytoskeleton and subsequent cell
migration. These data provided molecular mechanistic evidence for the multifaceted Hsp90
as a metastasis promoter during the cancer progression and suggested targeting Hsp90 for the
prevention of cancer metastasis.

B4. Chemotherapeutic Resistance
Since HSPs’ cytoprotective effect is essential for cancer cell survival, it is not surprising
that HSPs targeted therapy is considered an interesting pharmacological intervention stategy
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for cancer treatment. To that end, there are currently 13 Hsp90 inhibitors entered into clinical
evaluation in cancer patients (Trepel et al 2010, Table 1). Most studies to identify Hsp90
inhibitors have concentrated on ligands binding to the N-terminal ATP-binding site, which
disrupts Hsp90’s ATPase activity and the ongoing ATP-dependent folding cycle. Because this
cyclic event requires multiple co-chaperone proteins, inhibition results in the destabilization,
ubiquitination, and ultimately proteasomal degradation of the client proteins, causing the
disruption of multiple oncogenic signaling pathways simultaneously.
It has recently been confirmed there is an association of the GRP78 chaperone with client
proteins of the Hsp70-Hsp90 complex, namely HER2, HER3, Akt and androgen receptor
(AR) were observed in prostate cancer. The association of AR and GRP78 expression in
untreated prostate cancer is novel and highlights the potential implication of targeting GRP78
as a novel molecular therapy in prostate cancer in both the hormone-naïve and
castrate-resistant states. However, one of the critical problems with Hsp90 inhibition is the
accumulation of Hsp70 after treatment, which can reduce cell death induced by Hsp90
inhibitors and therefore buffer their anti-tumor efficacy in the clinic. Those disappointing
results may be related to inherent Hsp90 inhibitors toxicity and induction of Hsp70 by
calcium mobilization and activation of TGF-β signaling pathway. Thus, Hsp70 inhibition
combined with anti-Hsp90 compounds could be an interesting strategy to eliminate the toxic
side-effects of Hsp90 inhibitors and enhance synergistic efficacy for the treatment of cancer.
Currently compounds designed for inhibition of Hsp70 function are targeting different
domains by interfering at specific steps within the chaperone dynamic cycle. For example,
15-deoxyspergulain (15-DSG) possibly interacts with the C-terminal EEVD motif

25

Table 1. Hsp90 Inhibitors
Hsp90 Inhibitor

Interaction Site

References

Source

Geldanamycin

N-terminal ATP-binding

Supko 1995; Park 2003;Kim 2009; Samuni 2010

benzoquinone ansamycin antibiotic

17-AAG (Tanespimycin)

N-terminal ATP-binding

Janin 2005; Grem 2007; Erlichman 2009

Geldanamycin analog

17-DMAG

N-terminal ATP-binding

Palacios 2010

Geldanamycin analog

Retaspimycin hydrochloride

N-terminal ATP-binding

Hanson 2009; Dewaele 2008

IPI-504

IPI-493

N-terminal ATP-binding

Porter 2009; Croasdell 2010

Ansamycin class

Radicicol

N-terminal ATP-binding

Delmotte 1953; Soga 2003

Macrocylic antifungal

Purine-scaffold inhibitors

N-terminal ATP-binding

Zhang 2010

CNF-2024/BIIB021

Shepherin

N-terminal ATP-binding

Plescia 2005

Peptidomimetic antagonist

Pyrazoles (CCT-018159)

N-terminal ATP-binding

Rowlands 2004; Cheung 2005; Barril 2006; Sharp 2007

Antifungal antibiotic

PU24FCI

N-terminal ATP-binding

Vilenchik 2004

Synthetic inhibitor

SNX-5422(mesylate)

N-terminal ATP-binding

Huang et al 2009; Fadden 2010

Synthetic inhibitor

STA-9090

N-terminal ATP-binding

Lin 2008;Wang 2010

Resorcinol triazole

NVP-AUY922

N-terminal ATP-binding

Eccles 2008;Tauchi 2011;Gaspar 2010

Synthetic inhibitor

Oxime derivative KF58333

N-terminal ATP-binding

Soga et al 2001; Kurebayashi 2001

Synthetic inhibitor

Novobiocin

C-terminal ATP-binding*

Donnelly 2008; Yang 2003; Nordenberg 1992

From streptomyces

Coumermycin

C-terminal ATP-binding

Marcu 2000

From streptomyces

*The C-terminal ATP-binding site is putative
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to stimulate the steady-state ATPase activity of the constitutively expressed Hsc70 without
affecting Hsc70 functions that require DnaJ (Brodsky et al 1999). In addition, 15-DSG was
also found to bind Hsp90. Hsc70s are the constitutive cellular analogues of the
stress-inducible Hsp70 molecular chaperones, 70-kDa heat shock proteins that bind and
release polypeptide substrates concomitant with ATP-dependent dynamic cycle (Hartl 1996).
Nadeau et al utilized affinity capillary electrophoresis to obtain Kd values for DSG. Kd
values are 4 µM for DSG binding to Hsc70 and 5 µM for DSG binding to Hsp90. (Nadeau et
al 1994) Recently, a small molecule inhibitor Pifithrin-µ (2-phenylethynesulfonamide or
phenylacetylenylsulfonaminde, PES) was reported to interact with the substrate binding
domain of Hsp72 and to reduce the association between Hsp72 and its cochaperones Hsp40
and Bcl2-associated athanogene-1(BAG-1) (Leu et al 2009). Pifithrin-µ is an inhibitor of p53
binding capability and also an antiapoptotic protein. It can directly prevent p53 binding to
mitochondria as well as to Bcl-xL and Bcl-2 as a temporary inhibition of p53 transcriptional
activity to protect normal tissues from side effects by chemotherapy without affecting
p53-mediated transactivation in cancer treatment. Moreover, in vivo study also indicated that
administration of Pifithrin-µ inhibited spontaneous tumor development and enhanced
survival in the Eµ-Myc induced-lymphomagenesis mouse model (Leu et al 2009). However,
it would be interesting to investigate the effect on Hsp90 activity using Pifithrin-µ because
previous study showed dual siRNA knockdown of Hsc70 and Hsp72 led to the proteasomal
degradation of the Hsp90 client proteins CRAF, CDK4 and ERBB2 in human colon and
ovarian cancer cells (Powers et al 2008). Regarding the multiple functions of Hsp70 protein
for tumor growth, small molecule inhibitors targeting Hsp70 represents a promising approach
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to selectively target critical chaperone involvement in multiple oncogenic signaling
pathways.

C. Roles of HSPs in Other Diseases
Adaptation and survival to changeable environmental states requires a cell’s ability to
sense misfolded proteins and to activate the corresponding protective response, signaling
pathways, and functional molecular chaperones to restore intracellular homeostasis. Failure
to do so results in a cell that is poorly adapted to proteotoxic stimuli, so that when
dysfunctional aggregation of proteins occurs, the consequence is protein accumulation rather
than degradation of protein complexes. There are many protein conformation diseases
including cancer, neurodegenerative disease, aging, and chronic metabolic disease, some of
which will be discussed.

C1. Aging and Senescence
Misfolding and aggregation of proteins are now considered as common molecular events
in many human diseases. Conformational diseases have in common that aggregation-prone
proteins cause “gain-of-function” proteotoxicity and lead to several diseases due to improper
trafficking of proteins, misfolding or malfolded proteins, and inappropriate degradation of
proteins. Aging and protein synthesis homeostasis are intertwined closely. The molecular
interactions between the genetic pathways that regulate life span and inhibition of
proteotoxicity are promoted partially by factors including heat shock factor-1 (HSF-1),
molecular chaperones, and DAF-16 (a forkhead transcription factor found in C. elegans),
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which is closely related to mammalian transcriptional factor forkhead box O3A (FOXO3A).
HSF-1 is a transcription factor binding to Hsp40/Hsp70 and Hsp90 in a complex
formation under unstressed conditions, where Hsp90 is found as a suppressor of HSF-1
activation. Upon stress, HSF-1 forms trimers and becomes transcriptionally active because
Hsp90 needs to compete with misfolded proteins and dissociates from HSF-1. With age in
animal models, HSF-1 level does not change but a decline in the activation and binding of
DNA binding motif (Heydari et al 2000). Results from cultured cells suggest that the
age-related reduction in Hsp70 protein expression is due to decreased binding of HSF-1 to
the heat shock element (HSE) and declined Hsp70 transcription level. Overall, these
reductions of Hsp proteins and increase in misfolded protein all contribute to the damage of
molecular chaperone functions with age. (Horowitz et al 2007)
Dauer formation abnormal (DAF)-16 is a key FOXO transcription factor that regulates
innate immunity in Caenorhabditis elegans (Singh et al 2009). The human FOXO3A has
been linked to inflammation in response to infection. Recently, variants in FOXO3A have
consistently been confirmed with human longevity in different ethnic populations worldwide
(Flachsbart et al 2009). FOXO3A encodes an evolutionarily conserved key regulator of the
insulin-IGF1 signaling pathway that is known to influence metabolism and lifespan in model
organisms including worms, flies, mice in addition to human (Ziv et al 2011). Like FOXO3a,
the activity of DAF-16 is tightly regulated by a wide variety of external stimuli such as
nutrients, oxidative stress, and heat stress. Both HSF-1 and DAF-16 are essential partners and
play in concert to promote longevity and to maintain protein homeostasis (Kleindorp et al
2011).
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C2. Neurodegenerative Disease
Accumulation and deposition of misfolded proteins in the brain (inside and outside
neurons) and selective neuronal loss in the central nervous system (CNS) have been
implicated as a common molecular mechanism of various neurodegenerative diseases
including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis
(ALS), and the polyglutamine (PolyQ) diseases. Hsp27 protects motor neurons from
apoptosis induced by mechanical injury likely through intervention between cytochrome C
release and caspase-3 activation. Hsp70 has also been reported to associate with
polyglutamine proteins thereby prevention of its aggregation in vivo (Nagai et al 2010). The
PolyQ diseases are a group of nine hereditary neurodegenerative diseases, including
Huntington's disease (HD) and various types of spinocerebellar ataxia (SCA), which are
caused by abnormal expansions of the polyQ stretch (>35-40 repeats) in unrelated
disease-causative proteins. Misfolding and aggregation of the polyQ protein are the most
ideal therapeutic targets because they are the most upstream events in the pathogenic
progression, so that therapeutic approaches focusing on chaperones to prevent protein
aggregation and assist in the refolding of misfolded proteins, are being extensively studied.
Actually a variety of molecular chaperones such as Hsp70 and Hsp40 have been
demonstrated to exert therapeutic effects against various experimental models of the polyQ
diseases (Turturici et al 2011). Autosomal recessive juvenile Parkinsonism (ARJP) is caused
by parkin gene mutations, where parkin protein cooperates with Hsp70 and the co-chaperone
the E3 ubiquitin ligase C-terminus of Hsc70-interacting protein (CHIP) to suppress
Parkin-associated endothelin receptor-like receptor (Pael-R) function (Takahashi et al 2003).
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CHIP is believed to be a central player in the cellular triage decision, as it links the molecular
chaperones Hsp70/Hsc70 and Hsp90 to the ubiquitin proteasomal degradation pathway.
Loss of function of parkin, an ubiquitin ligase, is responsible for AR-JP. Pael-R was
identified using a yeast two-hybrid system and identified as a putative G protein-coupled
receptor protein is an authentic substrate of parkin (Takahashi et al 2003). It is thought to
accumulate abnormally following loss of parkin activity, causing neurodegeneration of nigral
dopaminergic neurons in AR-JP patients. Pael-R located in the ER membrane and promoted
ER stress-induced cell death through protein degradation and the ubiquitin-proteasome
pathway. When overexpressed in cells, this receptor becomes unfolded, insoluble, and finally
ubiquitinated. Accumulation of the insoluble Pael-R leads to ER stress-induced cell death.
Parkin specifically degrades the unfolded Pael-R, preventing cell death induced by the
aggregation of unfolded Pael-R (Dusonchet et al 2009).

C3. Kidney Diseases
The role of HSPs in chronic kidney disease (CKD) is relatively limited, though Hsp72
inhibits the proliferation and apoptosis in tubular cells in rats, decreases the accumulation of
fibroblasts and type I collagen in renal parenchyma, thereby delaying the fibrotic process.
Elevated Hsp90α in children with CKD indicates activated oxidative stress and inflammation
in CKD, which may ultimately trigger atherosclerosis. Clearly much more detailed molecular
and cellular analysis is needed, but current data suggests that the intracellular forms of Hsp70
slowed the progression of CKD through Hsp70’s anti-apoptotic and cytoprotective functions.
A variety of HSPs have shown their differing roles in CKD by protecting against stress
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conditions (Hsp70 and Hsp27), serving as a predictor of the cell damage (Hsp90), or acting
detrimentally on kidney function, glomerular necrosis, and anuria (Hsp60 and anti-Hsp60).
Thus, there is some indication that chaperones play an important role in CKD, although the
exact mechanistic functions attributed to each HSP still remain to be elucidated.
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CHAPTER THREE
THERAPEUTIC POTENTIAL OF HSP INHIBITION

A. Targeting Hsp90-mediated transformational signaling pathways in malignant cells
will comprehensively affect all the classic hallmarks of cancer progression.
Hanahan and Weinberg have proposed the six hallmarks of cancer a decade ago to
provide a logical and solid framework for understanding the biology of cancer (Hanahan et al
2000). With considerable progression made in cancer research after this publication, two
emerging hallmarks including reprogramming of energy metabolism and evading immune
destruction have become additional highlights in the study of tumorigenesis. In addition, two
enabling characteristics including tumor-promoting inflammation as well as genome
instability and mutation have been proved to enhance the six core and emerging hallmark
capabilities (Hanahan et al 2011). More importantly, in clinic pathological term
“desmoplasia” initially describing the growth of fibrous or connective tissue around the
tumor lesion has been proven and investigated in the mechanistic study of tumor progression,
which further complets our overall consideration of cancer cells not as an “isolated island”,
which means they have to communicate with and depend on surrounding non-cancerous cells
to facilitate tumor microenvironment. Microcommunity of cancer is not simply understood
by passive composition of bystanders but a dynamic microenvironment communication of
multiple cell types reciprocally interacting with each other to facilitate tumor progression,
especially tumor-associated fibroblasts or cancer-associated fibroblasts (TAFs or CAFs), a
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major and critical component of tumor stroma tissue (Tlsty et al 2006; Beacham et al 2005;
Kunz-Schughart et al 2002).
Appreciation of these critical hallmarks and characteristics for the development of
cancer will definitely modulate the future direction of cancer research and promote our
exploration of anti-tumor therapy with potential paradigm-shifting strategies (Hanahan et al
2011). As shown in Figure 1, Hsp90 plays a multifaceted part involved in the acquisition and
development of the hallmarks of cancer through interacting with many client proteins
responsible for essential oncogenic transformation. If these client proteins fail to bind a
specific ligand or receptor to form a meta-stable chaperone-client complex, then they are
subjected to ubiquitination and finally degraded by proteasome, providing the major
theoretical basis of pharmaceutical inhibition of Hsp90-mediated oncogenic signaling
pathways. For example, Hsp90 inhibitor was reported to inhibit angiogenic signaling
pathways either through HIF-dependent or -independent manner in the tumor vascularization
process.
Tumor cells activate endothelial cells through secretion of various proangiogenic growth
factors including VEGF, COX-2, Ang-2, HGF, FGF as well as Tie-2, which are regulated by
hypoxia through the hypoxia inducible factor (HIF) and bind to corresponding RTK on
dormant endothelial cells. Once endothelial cells become activated, they migrate and
proliferate to form novel branches from the preexisting blood vessels by secreting the matrix
metalloproteinases to detach from the extracellular matrix and basement membrane (Harris
2002). Major anti-angiogenic effects of Hsp90 inhibitors are most likely associated with
down-regulation of HIF activity, since the half life of HIF-1α is also controlled in an
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oxygen-independent way by the competitive binding of either Hsp90 to stabilize the protein,
or the anchoring protein Receptor for activated C kinase 1 (RACK1) to interact with Elongin
C and mediate prolyl hydroxylase domain protein 2 (PHD2) and von Hippel-Lindau protein
(VHL)-independent ubiquitination and degradation of HIF-1α (Semenza 2007). IL-8/NF-κB
signaling axis has been reported to upregulate VEGF expression through HIF-independent
proangiogenic processes, while suppression of NF-κB signaling in animal model of ovarian
cancer destroyed tumor angiogenesis with suppression of VEGF and IL-8 (Huang et al 2000).
Furthermore, Hsp90 inhibitors-mediated suppression of NF-κB was observed in several
studies. Taken together, these data suggested that Hsp90 inhibition reduced NF-κB activation
in tumor angiogenesis through IL-8 mediated signaling pathway.
RTKs are transmembrane proteins that transport the extracellular signals to the
intracellular context thereby regulating certain critical cellular events and tumor hallmark
such as angiogenesis. Given that RTKs comprise the largest category of Hsp90 client proteins,
it is promising to suppress angiogenic signalings and ameliorate therapeutic resistance using
Hsp90-targeted inhibitors, since acquired

chemoresistance is a common challenge for

application of tyrosine kinase inhibitors (TKIs) as anti-angiogenic approach because of
activation of compensatory and redundant signaling in several cancer types ( Bohonowych et
al 2010). For example, the family of platelet-derived growth factor (PDGF)/fibroblast growth
factor (FGF)/VEGF signaling axis has been reported to play a critical role for angiogenesis in
several transformed cells of malignancy. Mutations and upregulation of PDGF-receptor α and
β have been observed in human cancers to regulate vascular permeability and VEGF
expression. Crawford et al reported PDGF-C as a key mediator of tumor-associated
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fibroblasts (TAFs)-induced angiogenesis from resistant EL4 tumors, which are refractory to
anti-VEGF treatment. In the same study, neutralizing antibody against PDGF-C blocked
angiogenesis in such TAFs and slowed down the tumor growth with anti-VEGF resistance
(Crawford et al 2009). These findings suggested that a combination therapy utilizing
anti-PDGF-C and anti-VEGF antibodies may be more effective and synergistic than
anti-VEGF treatment alone. Moreover, this study also indicated that exposure of tumor cells
to anti-VEGF therapy may stimulate them switch to another survival signaling, in this case,
upregulation of PDGF-C inducing angiogenesis in vivo produced by those TAFs from
anti-VEGF-refractory tumors.
Several chemo-resistance molecular mechanisms have been uncovered in both
preclinical and clinical studies that activate partially redundant signaling pathways regulating
the hallmarks of cancer, including EGF/IGF/HGF/VEGF proangiogenic signaling pathways,
and PDGF/FGF/VEGF signaling module (Bohonowych et al 2010). In response to
therapeutic killing, cancer cells develop a large scope of compensatory and interconnected
mechanisms to cope with a variety of individually-targeted treatment. These evidences
strongly support the use of combinational therapy as a complementary means to combat
chemo-resistance induced by redundancy of oncogenic signalings in human cancers. Given
that the majority of these oncogenic proteins identified as Hsp90 client proteins,
Hsp90-directed pharmacological intervention becomes promising for broad suppression of
these signaling interactions within the tumor progression.
TAFs/CAFs is a pivotal component in the TAFs/CAFs-rich stroma contributing to
tumorigenesis. Accumulating evidences indicate targeting those fibroblasts may facilitate
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anti-cancer therapy by affecting oncogenic interactions between cancer cells and the assorted
cell types constituting the tumor microenvironment. Intriguingly, Hsp90 inhibitors
suppressed the reactive stroma phenotype in hepatic stellate cells and induced
caspase-8-mediated apoptosis via sphingomyelinase- and NF-κB-dependent pathways
(Myung et al 2009). In addition, Akt/PI3K and MAPK signaling pathways were activated in
pancreatic stellate cells and colon cancer through upregulation of periostin, a component of
extracellular matrix to promote tumor metastasis and invasion (Erkan et al 2007;Bao et al
2004), suggesting targeting Hsp90-client oncogenic signalings may represent a novel
approach for anti-stroma regimen in the future even though these area are still at rudimentary
stage and await to be investigated further.

B. Exploration of small molecule inhibitors of Hsp90 activity: Small molecule inhibitors
targeting Hsp90 with minimum off-target effects should be considered for cancer
treatment.
Almost two decades ago, Whitesell et al firstly demonstrated Hsp90-involved heteroprotein
complex formation was required for v-src-mediated morphologic transformation and
benzoquinone ansamycins such as Geldanamycin (GA),

can inhibit Hsp90-src through

competitive binding to Hsp90 (Whitesell et al 1994). Subsequently studies of HSPs-targeted
anti-tumor therapy proliferated in both preclinical and clinical stages (Table I, II and III).
Recently, Roué et al reported the Hsp90 inhibitor IPI-504 (retaspimycin hydrochloride)
restored drug sensitivity in proteasome inhibitor bortezomib-resistant aggressive mantle cell
lymphoma (MCL) (Roué et al 2011). In their study, one of Hsp70 family members,
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BiP/GRP78 was up-regulated in aggressive B-cell malignancies including MCL and was
responsible for constitutive or induced-bortezomib resistance. IPI-504 in combination with
bortezomib dissociated Hsp90-BiP/GRP78 complex, causing the latter to be depleted thus
affecting the UPR and restoring apoptosis (Roué et al 2011). These findings added a novel
function of Hsp90 in cancer treatment by inhibition of UPR-related oncogenic phenotypes
including drug resistance and evasion of apoptosis. With the help of X-ray crystallography
and structure-based drug design to improve potency, a second class of synthetic Hsp90
inhibitors have been reported, NVP-AUY922 (Novartis) is a novel Hsp90 inhibitor and has
the highest affinity for the NH2-terminal ATP-binding site among synthetic small molecule
inhibitors. Effects of NVP-AUY922 include inhibition and/or repression of tumor growth in
tumor xenografts with a variety of types of human cancers, blockage of tumor cell invasion
and metastasis both in vitro and in vivo, and depletion of client proteins including BCR-ABL,
ERBB2, CRAF, CDK-4, AKT and HIF-α (Eccles et al 2008).
Recent studies show impressive synergistic action of NVP-AUY922 with melphalan,
doxorubicin, NVP-LBH589, and suberoylanilide hydroxamic acid (SAHA) in multiple
myeloma and build the experimental foundation for clinical trials (Kaiser et al 2010). Of
notice, cell surface Hsp90 was found on melanoma cells, fibrosarcoma cells, bladder cancer
cells, prostate cancer cells as well as neuronal cells and play an important role to control
cancer cell migration independent of intracellular Hsp90 pool function (Tsutsumi et al 2008).
Intriguingly, extracellular Hsp90α once hyperacetylated by HDAC inhibitor acted as a
chaperone for MMP-2 to promote tumor cell invasion, suggesting inhibition of extracellular
hyperacetylated Hsp90α may affect tumor invasion and metastasis (Yang et al 2008).
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Table 2. Hsp90 Inhibitors in Clinical Trials
Clinical

Hsp90 Inhibitor

Trial Phase

Cancer

References

Geldanamycin

I*

thyroid (hepatotoxicity in vivo)

Supko 1995; Park 2003;Kim 2009; Samuni 2010

17-AAG (Tanespimycin)

II/III

breast, leukemia, prostate

Janin 2005; Grem 2007; Erlichman 2009

17-DMAG

I

breast, leukemia

Palacios 2010

Retaspimycin hydrochloride

I/II/III

NSLC, GIST, pancreatic, MCL

Hanson 2009; Dewaele 2008

IPI-493

I

advanced solid tumors

Porter 2009; Croasdell 2010

Radicicol

I

in vitro (no + in vivo results)

Delmotte 1953; Soga 2003

Purine-scaffold inhibitors

I

Hodgkin's lymphoma, CLL

Zhang 2010

Shepherin

-

leukemia (animal model)

Plescia 2005

Pyrazoles (CCT-018159)

-

prostate cancer (in vitro)

Rowlands 2004; Cheung 2005; Barril 2006; Sharp 2007

PU24FCI

II

breast, CLL, SCLC

Vilenchik 2004

Mesylate (SNX-5422)

I

HT-29 model

Huang 2009; Fadden 2010

STA-9090

I

mast cell tumors

Lin 2008;Wang 2010

NVP-AUY922

-

breast, prostate, GBM, MM

Eccles 2008;Tauchi 2011;Gaspar 2010

Oxime derivative KF58333

-

breast (in vitro)

Soga 2001; Kurebayashi 2001

Novobiocin

II

breast and melanoma (in vitro)

Donnelly 2008; Yang 2003; Nordenberg et al 1992

Coumermycin A1

-

breast (in vitro)

Marcu 2000

Cisplatin

I/II/III/IV

head and neck

Donnelly 2008; Ashan 2010

AR-42 (HDAC6)

I

mast cell tumors, MM, B-cell

Lin 2010; Zhang 2010; Lucas 2010

Vorinostat/SAHA (HDAC6)

I/II

Leukemia, head and neck

Kovacs 2005; Yang 2008; Blumenschein 2004

Romidepsin/FK228 (HDAC6)

II

T-cell lymphoma

Chen 2005; Piekarz 2011

*Clinical Trial suspended
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Table 3. Chemotherapy Drugs that Synergize with Hsp90 Inhibitors
Clinical
Trial Phase

Disease

References

17-DMAG + arsenic oxide

-

leukemia

Wu et al 2009

17-AAG + Gleevec/imatinib

-

leukemia, breast cancer

Radujkovic et al 2005

17-AAG + bortezomib

II

multiple myeloma

Richardson et al 2010

17-AAG + HDAC-6 siRNA

-

leukemia

Rao et al 2008

IPI-504 + Gleevec/imatinib

-

leukemia (mouse model)

Peng et al 2007

Drug Combinations
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Definition of four phases clinical trial from NIH:
Phase I clinical trials test a new biomedical intervention in a small group of people (e.g.,
20-80) for the first time to evaluate safety (e.g., to determine a safe dosage range and to
identify side effects).
Phase II clinical trials study the biomedical or behavioral intervention in a larger group of
people (several hundred) to determine efficacy and to further evaluate its safety.
Phase III studies investigate the efficacy of the biomedical or behavioral intervention in large
groups of human subjects (from several hundred to several thousand) by comparing the
intervention to other standard or experimental interventions as well as to monitor adverse
effects, and to collect information that will allow the intervention to be used safely.
Phase IV studies are conducted after the intervention has been marketed. These studies are
designed to monitor effectiveness of the approved intervention in the general population and
to collect information about any adverse effects associated with widespread use.

Summary of Hsp90 inhibitors in the current clinical trial
Hsp 90 inhibitors are composed of two major classes, natural products and synthetic
products. Natural products include Geldanamycin (GA) and radicicol (RD) as well as their
derivatives. They modulate Hsp90 molecular chaperone function in a similar manner and
have comparable biological activity. Synthetic inhibitors include purine and pyrazoles as well
as their derivatives, which have been discovered by structure-based design, fragment-based
design, high throughput screening as well as virtual screening.
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Figure 3. Chemical structure of Geldanamycin (GA)-related compounds. The ‘R’ group
in GA can be replaced with the indicated side group to make the following compounds:
Tanespimycin
(17-AAG),
17-amino-17-demethoxygeldanamycin
(17-AG),
17-dimethylaminothylamino-17demethoxy-geldanamycin (DMAG) (Refer to Erlichman
2009).
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GA is a potent cytotoxic drug but has been terminated in the clinical trial due to several
reasons including severe hepatotoxicity, unstable metabolism and chemical structure as well
as poor solubility. A substantial effort has been devoted to modify its structure to overcome
aforementioned side effects. 17-AAG (Tanespimycin) is a result of the relative ease with
which the C-17 methoxy group substituted by amino and small unhindered alkylamino
groups. Kosan Pharmaceuticals developed a DMSO-free formulation of 17-AAG in the
combination with other drugs such as trastuzumab or bortezomib, which resulted in
encouraging clinical results reported in trastuzumab-resistant HER2-positive breast cancer
and in multiple myeloma patients even if refractory to bortezomib. 17-DMAG was designed
by the NCI and Kosan as a more soluble analogue of 17-AAG. 17-DMAG entered clinical
trials in 2005 to treat patients with acute myeloid leukemia (AML) and was discontinued at
the beginning of 2008.
Retaspimycin hydrochloride (IPI-504) and Alvespimycin (IPI-493/KOS-1022) are the
second generation Hsp90 inhibitors developed by Infinity to treat different types of cancer.
These drugs show higher solubility exemplified by IPI-504 being 400-fold more soluble than
17-AAG. As a highly soluble hydroquinone hydrochloride derivative of 17-AAG, IPI-504 has
entered the clinical trials in phase III for gastrointestinal stromal tumor (GIST), phase II for
non-small-cell lung cancer (NSCLC) and breast cancer, phase I for sarcoma and multiple
myeloma. IPI-493 is a water-soluble, stable GA derivative 17-DMAG with limited
metabolism and higher oral bioavailability, demonstrating more potent in vitro and in vivo
anti-tumor effect than 17-AAG. It has entered in phase I clinical trial for advanced solid
tumors (Porter et al 2009; Croasdell et al 2010).
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Radicicol (RD) is a macrocyclic lactone antibiotic first purified from the fungus
Monosporium bonorden. RD has no in vivo activity due to instability in serum. In order to
enhance its in vivo activity, oxime derivatives have been synthesized to reduce the
electrophilicity of the Michael acceptor. KF58333 demonstrated potent anti-proliferative
activity against all breast cancer cell lines tested in vitro and depleted hsp90 client proteins
such as erbB2, raf-1 and Akt in the tumor tissues from nude mice (Soga et al 2001).
The basis of the designing the first synthetic Hsp90 inhibitors was using ATP mimics
composed of a purine structure tethered by a linker to adjacent aryl moiety to form the
C-shaped conformation. This unique shape can compete with ATP for binding to the
N-terminal nucleotide pocket of Hsp90. As a purine-scaffold modified drug, PU24FCI results
in multiple anti-tumor activities through degradation of Hsp90-client proteins including
HER-2, Akt and Raf-1 in tumors. In addition it demonstrates 10- to 50- fold higher binding
affinity to Hsp90 from transformed cells and has entered phase II clinical trial for breast
cancer, small-cell lung cancer and chronic lymphocytic leukemia (CLL).
Pyrazoles and isoxazoles represent another novel scaffold to be characterized and
developed as Hsp90 inhibitors. CCT-018159 was discovered by a high throughput screening
against a 50,000 compounds library and had good activity in a proliferation assay using
HCT116 colon cancer cells. isoxazoles are chemically related to pyrazoles as a novel type of
Hsp90 inhibitors by binding to the N-terminal ATP pocket. These derivatives demonstrated
promising effect in the cell growth inhibition assay exemplified by NVP-AUY922, which has
entered phase I clinical trial for advanced cancer.
Serenex developed an oral Hsp90 inhibitor, Mesylate (SNX-5422), which has entered
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phase I clinical trial for evaluation of some types of cancers, although the structures are not
reported. Synta developed an intravenous Hsp90 inhibitror, STA-9090, which as entered
phase I/II clinical trial for solid tumors and hematologic Malignancies. There are no clinical
data available using aforementioned synthetic inhibitors, however, it is worthy to expect
intriguing results form these studies.
Cisplatin is a FDA approved drug to be used alone or with other drugs to treat several
types of cancer (http://www.cancer.gov/cancertopics/druginfo/cisplatin). It is also being
investigated in the other types of cancer. Cisplatin is an inorganic platinum agent
(cis-diamminedichloroplatinum) with anti-tumor activity. It can form highly reactive, charged,
platinum complexes to bind to GC-rich sequences in DNA, inducing intra-strand and
inter-strand DNA crosslinks, as well as DNA-protein crosslinks, finally leading to apoptosis
and cell growth inhibition. It has been reported that Cisplatin prevents Hsp90 from interacting
with hormone receptors, such as AR and GR. In vitro study in pediatric cancers also showed
combinational therapy using Cisplatin and GA suppressed the ability of GA to induce a
cytoprotective heat shock response and resulted in synergistic anticancer acitivity (Bagatell et
al 2005).
HDAC inhibitors including suberoylanilide hydroxamic acid (SAHA), FK228 and
AR-42 have been reported in clinical trials for evaluation of the treatment of several types of
cancer. SAHA or Vorinostat is a member of a larger class of compounds that inhibit histone
deacetylases (HDAC), which remove the acetyl groups on the DNA backbone, increase the
positive charge of histone tails on the amine groups and high-affinity binding between the
histones and DNA backbone and finally prevents transcription. The effect of Hsp90
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acetylation on chaperone function exerted by HDAC inhibitors has been extensively studied
in several types of cancer models (Rao et al 2008; Yang et al 2008; Wanczyk et al 2011).
Novobiocin is an aminocoumarin antibiotic produced by the actinomycete Streptomyces
niveus, which was also subjectively called S. spheroides. Other aminocoumarin antibiotics
include clorobiocin and coumermycin A1. These compounds can bind type II topoisomerases,
including DNA gyrase, thereby inhibiting the enzyme-catalyzed hydrolysis of ATP as good
candidates for research of the treatment of bacterial infection.
The C-terminal binding domain of Hsp90 was reported to bind not only ATP, but also
cisplatin, novobiocin, epilgallocatechin-3-gallate (EGCG) and taxol. Novobiocin binds
weakly to the Hsp90 C-terminal ATP binding site but structural modification can improve this
compound binding affinity with1,000 higher in anti-proliferation assay. Novobiocin entered
in one phase II clinical trial when in combination with high-dose chemotherapy for the
treatment of advanced breast cancer, Clinical data did not translate into a substantial increase
progression-free survival (PFS) and overall survival (OS),compared with controls treated
with high-dose alkylator therapy alone (Hahm et al 2000).
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CHAPTER FOUR
CONCLUSIONS & FUTURE DIRECTIONS

It was originally held that Hsp90 function was solely associated with the stabilization
the nascent proteins and protein complexes in the cytoplasm, while subsequent work showed
a multifaceted role for HSPs in intracellular transport, maintenance and degradation of client
proteins, and participation in many biochemical signaling pathways to preserve intracellular
homeostasis. An immense amount of work has been done, and continues to be done, to
progress the field over the last two decades, focusing substantially on Hsp90-asscociated
client proteins, which play a complex role in the maintenance of each of the core intracellular
signaling networks relevant to the Hallmarks of Cancer. Many Hsp90 inhibitors capable of
binding within either the N- and C-terminal domains of Hsp90 have been found, synthesized,
and characterized, and many have proven useful for treating a variety of human diseases
including cancer (Tables I, II).
However, information from animal studies and clinical trials has not shown substantial
progress in the use of Hsp90 inhibition as a first line of defense, suggesting that Hsp90
inhibition would be infinitely more affective in combination with other therapies. Here, we
summarize many of the current combinational therapies or treatments using Hsp90 inhibitors
from both clinical trials and laboratory studies (Table III). Many combinations show a
synergistic effect when compared to individual, independent drug treatment in several types
of cancers. Of note, however, a synergistic effect was not observed in several murine solid
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tumor models compared to blood-related cancers, likely due to the inherent differences
between these types of cancers, their tumor microenvironment, the effective delivery of the
compounds, and other as yet unknown factors. Quite possibly, there exists redundant
signaling pathways that may be activated in solid tumors, promoting increased survival as a
consequence. For example, initial clinical studies showed that targeting angiogenic signaling
in human glioblastomas allowed tumor cells to shift toward invasiveness and metastasis,
resulting in the tumor cells having access to pre-existent blood vessels within the surrounding
normal tissue vasculature (Ellis et al 2009; Verhoeff et al 2009; Norden et al 2009). Moreover,
the molecular heterogeneity of cancers exemplified by the elaborate integrated signaling
circuitry clearly influences the therapeutic killing effect. To complicate matters, differential
client protein affinity with Hsp90 in a variety of cancer types, as well as within desmoplastic
tumor microenvironment (like CAFs), can be supportive factors for inducing resistance to
therapeutic treatment.
In order to consider a regimen targeting Hsp90 in a broad sense, the following
suggestions should be considered for both future basic science and clinical studies, as well as
when assessing the utility and effectiveness of Hsp90-targeted approaches:
1.

Inhibiting Hsp90 in combination with other heat shock proteins, such as Hsp70 and
Hsp27, which may be an alternative strategy to enhance synergistic cancer therapy
with minimum off-target side effect. As mentioned earlier, Hsp90 inhibition was
reported to upregulate Hsp70 and Hsp27 expression in tumor cells in order to
prevent apoptosis.

2.

Additional studies should be accomplished to define the precise molecular
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mechanism(s) of Hsp90 client proteins responsible for the unique phenotypes in
different types of cancer in order to understand the exact Hsp90 biochemical
functions implicated in multiple oncogenic signaling networks. This will ultimately
allow for the identification of reliable biomarkers for monitoring the effects of
Hsp90 suppression in vivo, as well as for optimizing drug transmission and
treatment efficacy through various combinational therapies targeting major
oncogenic signaling pathways.
3.

The use of specific cellular or subcellular targeting for chaperones needs to be
considered and developed. Accumulating evidence suggests alternative locations of
HSPs, especially Hsp90 inside or outside of the cells, in the cytoplasm, in the
nucleus, etc., which indicates it plays a unique role as part of a tumor-specific
phenotype. Therefore, development and validation of cell-location-specific
inhibitors will benefit Hsp90 targeted chemotherapy in human cancer, especially
when used in combination with efficient delivery approaches.

4.

Screening of novel chemical structures with increased solubility and stability in
vivo will provide the potential for oral administration in the clinic in order to
eliminate the current issues of hepatoxicity and limited solubility related to some
Hsp90 inhibitors.
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